Table 1 Candidate demographics, cPRA and clinical outcomes
From: B cell repertoires in HLA-sensitized kidney transplant candidates undergoing desensitization therapy
|  | Controls (n = 7) | Responders (n = 11) | Non-responders (n = 8) |
|---|---|---|---|
Age (years) | 45 ± 11 | 40 ± 12 | 43 ± 7 |
Male/female | 4/3 | 7/4 | 2/6 |
Race | |||
 White | 3 | 3 | 4 |
 Black | 1 | 3 | 1 |
 Hispanic | 1 | 1 | 3 |
 Asian | 2 | 3 | 0 |
 Native American | 0 | 1 | 0 |
Cause of ESRD | Â | Â | Â |
 Diabetes | 0 | 2 | 1 |
 Glomerulonephritis | 4 | 1 | 1 |
 SLE | 1 | 3 | 1 |
 PKD | 0 | 1 | 1 |
 Congenital | 0 | 3 | 0 |
 Other | 2 | 1 | 4 |
Cumulative cPRA (%) | |||
 Before desensitization | 13 ± 16 | 97.4 ± 2.7 | 100 ± 0 |
 After desensitization | N/A | 87.9 ± 3.8 | 100 ± 0 |
Transplanted (%) | 7 (100) | 11 (100) | 3 (37.5) |
Donor type: DD:LUR:LRD | 1:0:6 | 8:2:1 | 2:1:0 |
Rejection | |||
 Borderline acute | 0 | 3 (27) | 1 (33) |
 Cell mediated | 0 | 1 (9) | 0 |
 Antibody mediated | 0 | 0 | 0 |
Graft loss (%) | 0 | 0 | 0 |
Death-censored graft survival (1Â year) | 100% | 100% | 100% |